Other News To Note
Friday, February 4, 2011
Digna Biotech SL, of Madrid, Spain, and the Centro de Investigacion Medica Aplicada de la Universidad de Navarra said the European Union finalized a 3.3 million (US$4.5 million) grant to AIPGENE consortium and, as members of the consortium, Digna and CIMA will receive 500,000 and 800,000, respectively, for the clinical development of a gene therapy product for acute intermittent porphyria. As part of the grant, they will complete a Phase I/II study, with patient enrollment slated to start in early 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.